Ngm18-0402- A Phase 1A/B Dose-Escalation Study Followed By Expansion Cohorts Of Ngm120, A Gfral Antagonist Monoclonal Antibody Blocking Gdf15 Signaling, In Subjects With Advanced Solid Tumors And Pancreatic Cancer Using Combination Therapy
Posted Date: Feb 24, 2020
- Investigator: Shuchi Gulati
- Specialties: Cancer, Oncology, Pancreatic Cancer
- Type of Study: Drug
The main goal of this study is to determine the safety and tolerability, and maximum tolerated dose of NGM120 alone, and NGM120 when administered in combination with gemcitabine+Abraxane in subjects with select solid tumors,for the management of metastatic pancreatic cancer.
Criteria:
To Be Eligible: Must Have Ecog 0-1, Life Expectancy >12 Weeks, Progressive Disease For Which No Effective Therapies Are Available, Active Infections Or Medical Disorders That May Impact Treatment
Keywords:
Pancreatic Cancer, Oncology
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com